论文部分内容阅读
目的评价青蒿琥酯及蒿甲醚治疗间日疟(G6PD)缺乏患者的疗效与安全性。方法采用A)青蒿琥酯静注5d疗程总量360mg和(B)蒿甲醚肌注3d疗程总量560mg各治疗间日疟30例,病例经G6PD活性检测《60%列为对象,住院7d,追踪观察至28d,进行随机比较。结果AB两组病例均能迅速控制临床症状,平均退热时间(d)分别为18。3d和19。2d。(38.3±0.4VS38.5±0.6)、平均原虫转阴时间(d)(16.3±22.23VS23.8±27.9)、治愈率(53.3%VS56.7%)、复燃率(46.7%VS43.3%)等方面均无显著差异(P>0.05)。两组极少数病例只见轻微的恶心或呕吐,未见其它明显毒副作用。结论青蒿琥酯及蒿甲醚治疗间日疟在控制症状、退热、原虫转阴等临床效果都很好,但复燃率很高。很难替换伯氨喹。
Objective To evaluate the efficacy and safety of artesunate and artemether in the treatment of patients with G6PD deficiency. Methods A) artesunate intravenous injection of 5d total amount of 360mg and (B) artemether intramuscular injection of 3d course of treatment of total amount of 560mg vivax malaria in 30 cases, the case by G6PD activity test "60% as a target, hospitalization 7d, follow-up observation to 28d, for random comparison. Results The clinical symptoms of patients in both AB groups were rapidly controlled. The average antipyretic time (d) was 18.3 days and 19.2 days respectively. (38.3 ± 0.4VS38.5 ± 0.6), average protozoa (16.3 ± 22.23VS23.8 ± 27.9), cure rate (53.3% vs56.7%), and resuscitation rate (46.7% VS43.3 %), Etc. There was no significant difference (P> 0.05). A very small number of cases showed mild nausea or vomiting in both groups, with no other obvious side effects. Conclusion Artemisia and Artemether treatment of vivax malaria in the control of symptoms, fever, protozoa negative and other clinical effects are good, but the high rate of relapse. Difficult to replace primaquine.